BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8918409)

  • 1. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Cancer; 1996 Nov; 78(10):2157-63. PubMed ID: 8918409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer.
    Nicoletto MO; Tumolo S; Sorio R; Cima G; Endrizzi L; Nascimben O; Vinante O; Artioli G; Donach M; Cartei G;
    Int J Gynecol Cancer; 2007; 17(5):986-92. PubMed ID: 17316364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
    Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
    Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
    Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
    Goff BA; Sainz de la Cuesta R; Muntz HG; Fleischhacker D; Ek M; Rice LW; Nikrui N; Tamimi HK; Cain JM; Greer BE; Fuller AF
    Gynecol Oncol; 1996 Mar; 60(3):412-7. PubMed ID: 8774649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
    Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
    Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
    Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
    Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
    Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
    Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
    Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
    Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Yamamuro O; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
    Int J Gynecol Cancer; 2012 Sep; 22(7):1143-9. PubMed ID: 22801028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.